Literature DB >> 18515102

Design and synthesis of 4-HPR derivatives for rhabdoid tumors.

Bhaskar C Das1, Melissa E Smith, Ganjam V Kalpana.   

Abstract

Rhabdoid tumors (RTs) are aggressive pediatric malignancies with poor prognosis that arise due to loss of the hSNF5/INI1 tumor suppressor. Molecular studies indicate that cyclin D1, a downstream effector of INI1 is up regulated in RT, and is essential for this tumor formation. Previously we demonstrated that 4-HPR, a synthetic retinoid that targets Cyclin D1, is a potential chemotherapeutic agent for RT. To facilitate further chemical development of this retinoid, and to determine its active moiety, we synthesized small chemical libraries of 4-HPR and tested their cytotoxic effect on RT cells. We synthesized 4-HPR (1) and the derivatives (5a-5n) starting from retinoic acid. First, retinoic acid was converted to acid chloride derivatives, then in the presence of DMF, base, and aniline derivatives, we synthesized the corresponding 4-hydroxy phenyl amine derivatives (5a-5n). This procedure gave 70-90% yield. Then, the 4-HPR derivatives were tested for their ability to inhibit RT cells using an in vitro cell survival assay. We found that the 4-hydroxy group at para-position is essential for cytotoxic activity against RT cells. Furthermore, we identified a few derivatives of 4-HPR with higher cytotoxic potencies than 4-HPR. In addition, we demonstrate that either chloro, fluoro or iodo derivatives at meta-position of phenyl ring retain the cytotoxic activity. Interestingly, substitution of iodo-moiety at meta-position (5j) substantially increased the efficacy (IC(50) approximately 3muM, Fig. 1D). These results indicate that chemical modification of 4-HPR may result in derivatives with increased therapeutic potential for RTs and that halogen substituted 4-HPR that retain the activity can be synthesized for further therapeutic and diagnostic use.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18515102     DOI: 10.1016/j.bmcl.2008.05.021

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  9 in total

1.  The hydroxyl functional group of N-(4-hydroxyphenyl)retinamide mediates cellular uptake and cytotoxicity in premalignant and malignant human epithelial cells.

Authors:  Numsen Hail; Ping Chen; Michael F Wempe
Journal:  Free Radic Biol Med       Date:  2010-10-23       Impact factor: 7.376

Review 2.  Retinoic acid signaling pathways in development and diseases.

Authors:  Bhaskar C Das; Pritam Thapa; Radha Karki; Sasmita Das; Sweta Mahapatra; Ting-Chun Liu; Ingrid Torregroza; Darren P Wallace; Suman Kambhampati; Peter Van Veldhuizen; Amit Verma; Swapan K Ray; Todd Evans
Journal:  Bioorg Med Chem       Date:  2013-11-22       Impact factor: 3.641

3.  Design and Synthesis of 3,5-Disubstituted 1,2,4-Oxadiazole Containing Retinoids from a Retinoic Acid Receptor Agonist.

Authors:  Bhaskar C Das; Xiang-Ying Tang; Swarnava Sanyal; Seetaram Mohapatra; Patrick Rogler; Sabita Nayak; Todd Evans
Journal:  Tetrahedron Lett       Date:  2011-05-11       Impact factor: 2.415

4.  Design, synthesis and biological study of pinacolyl boronate-substituted stilbenes as novel lipogenic inhibitors.

Authors:  Bhaskar C Das; Xiaoping Zhao; Xiang-Ying Tang; Fajun Yang
Journal:  Bioorg Med Chem Lett       Date:  2011-06-28       Impact factor: 2.823

5.  SNF5 reexpression in malignant rhabdoid tumors regulates transcription of target genes by recruitment of SWI/SNF complexes and RNAPII to the transcription start site of their promoters.

Authors:  Yasumichi Kuwahara; Darmood Wei; Joel Durand; Bernard E Weissman
Journal:  Mol Cancer Res       Date:  2013-01-30       Impact factor: 5.852

6.  Design and synthesis of boron containing potential pan-RAR inverse agonists.

Authors:  Bhaskar C Das; Xiang-Ying Tang; Todd Evans
Journal:  Tetrahedron Lett       Date:  2012-01-03       Impact factor: 2.415

7.  Novel retinoic acid receptor alpha agonists for treatment of kidney disease.

Authors:  Yifei Zhong; Yingwei Wu; Ruijie Liu; Zhengzhe Li; Yibang Chen; Todd Evans; Peter Chuang; Bhaskar Das; John Cijiang He
Journal:  PLoS One       Date:  2011-11-18       Impact factor: 3.240

8.  In vitro activities of novel 4-HPR derivatives on a panel of rhabdoid and other tumor cell lines.

Authors:  Melissa E Smith; Bhaskar C Das; Ganjam V Kalpana
Journal:  Cancer Cell Int       Date:  2011-09-27       Impact factor: 5.722

9.  Small molecules targeting LapB protein prevent Listeria attachment to catfish muscle.

Authors:  Ali Akgul; Nawar Al-Janabi; Bhaskar Das; Mark Lawrence; Attila Karsi
Journal:  PLoS One       Date:  2017-12-18       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.